12月10日的资金流向数据方面，主力资金净流出204.73万元，占总成交额2.77%，游资资金净流入31.46 万元，占总成交额0.43%，散户资金净流入173.27万元，占总成交额2.34%。 近5日资金流向一览见下表： 证券之星消息，截至2025年12月10日收盘，心脉医疗(688016)报收于91.62元，上涨0.22%，换手率 0.66%，成交量8110.0手，成交额7391.49万元。 心脉医疗2025年三季报显示，前三季度公司主营收入10.15亿元，同比上升4.66%；归母净利润4.29亿 元，同比下降22.46%；扣非净利润3.72亿元，同比下降25.8%；其中2025年第三季度，公司单季度主营 收入3.0亿元，同比上升64.68%；单季度归母净利润1.14亿元，同比下降23.63%；单季度扣非净利润1.02 亿元，同比下降11.84%；负债率15.85%，投资收益1160.33万元，财务费用-785.84万元，毛利率 70.4%。心脉医疗（688016）主营业务：主动脉及外周血管介入医疗器械的研发、生产和销售。 该股最近90天内共有9家机构给出评级，买入评级7家，增持评级2家；过去90天内机构 ...

证券之星消息，截至2025年12月8日收盘，心脉医疗(688016)报收于93.1元，下跌0.09%，换手率 0.72%，成交量8897.0手，成交额8306.01万元。 12月8日的资金流向数据方面，主力资金净流入319.21万元，占总成交额3.84%，游资资金净流入379.45 万元，占总成交额4.57%，散户资金净流出698.66万元，占总成交额8.41%。 近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净流入 游资净占比 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-12-08 | 93.10 -0.09% | | 319.21万 | 3.84% | 379.45万 | 4.57% | -698.66万 | -8.41% | | 2025-12-05 | 93.18 | 1.28% | -442.24万 | -5.52% | -102.43万 | -1.28% | 544.67万 | 6.80% | | 2025-12-04 | | 92. ...

该股主要指标及行业内排名如下： 证券之星消息，截至2025年12月5日收盘，心脉医疗(688016)报收于93.18元，上涨1.28%，换手率 0.7%，成交量8673.0手，成交额8010.91万元。 12月5日的资金流向数据方面，主力资金净流出442.24万元，占总成交额5.52%，游资资金净流出102.43 万元，占总成交额1.28%，散户资金净流入544.67万元，占总成交额6.8%。 近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净点比 游资净占比 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-12-05 | 93.18 | 1.28% | -442.24万 | -5.52% | -102.43万 | -1.28% | 544.67万 | - 6.80% | | 2025-12-04 | | 92.00 -0.12% | - -837.21万 | -8.37% | -82.97万 | -0.83% | 920.17万 | 9.20% | ...

截至9月30日，心脉医疗股东户数1.60万，较上期减少8.73%；人均流通股7708股，较上期增加9.56%。 2025年1月-9月，心脉医疗实现营业收入10.15亿元，同比增长4.66%；归母净利润4.29亿元，同比减少 22.46%。 分红方面，心脉医疗A股上市后累计派现10.79亿元。近三年，累计派现8.17亿元。 11月4日，心脉医疗盘中下跌2.00%，截至10:43，报100.20元/股，成交6044.41万元，换手率0.49%，总 市值123.51亿元。 资金流向方面，主力资金净流出424.60万元，特大单买入431.71万元，占比7.14%，卖出912.96万元，占 比15.10%；大单买入1172.43万元，占比19.40%，卖出1115.77万元，占比18.46%。 心脉医疗今年以来股价跌7.42%，近5个交易日跌3.73%，近20日跌6.31%，近60日跌10.67%。 资料显示，上海微创心脉医疗科技(集团)股份有限公司位于上海市浦东新区康新公路3399弄1号，成立 日期2012年8月17日，上市日期2019年7月22日，公司主营业务涉及主动脉及外周血管介入医疗器械的研 发、生产和销售。主 ...

Core Viewpoint - Xinmai Medical is a leading enterprise in the field of aortic and peripheral vascular interventional medical devices in China, with strong R&D capabilities and technical barriers [1] Group 1: Business Performance - In Q3 2025, Xinmai Medical reported revenue of 1.015 billion yuan, ranking 22nd among 50 companies in the industry [2] - The company's net profit for the same period was 423 million yuan, ranking 9th in the industry [2] - Revenue from aortic products was 514 million yuan, accounting for 71.94% of total revenue, while peripheral and other products generated 200 million yuan, making up 28.04% [2] Group 2: Financial Ratios - As of Q3 2025, Xinmai Medical's debt-to-asset ratio was 15.85%, lower than the industry average of 23.66% [3] - The company's gross profit margin was 70.40%, higher than the industry average of 48.78% [3] Group 3: Management and Shareholder Information - The chairman of the company is Jonathan Chen, who has a background in economics and biological sciences, and has held various positions in the medical field [4] - The total compensation for General Manager Zhu Qing decreased from 3.9439 million yuan in 2023 to 940,000 yuan in 2024, a reduction of 3.0039 million yuan [4] - As of September 30, 2025, the number of A-share shareholders decreased by 8.73% to 16,000 [5] Group 4: Market Outlook and Growth - According to Guojin Securities, Xinmai Medical's revenue for the first three quarters of 2025 increased by 5% year-on-year, while net profit decreased by 22% [6] - The company is expanding its overseas market, with overseas sales revenue growing by over 65% year-on-year [6] - Forecasted net profits for 2025, 2026, and 2027 are 603 million, 768 million, and 950 million yuan, respectively, with expected growth rates of 20%, 27%, and 24% [6]

Core Viewpoint - The stock of Xinmai Medical (688016) has shown a decline in both price and trading volume, with significant net outflows from retail and speculative investors, indicating potential concerns about the company's financial performance and market sentiment [1][2]. Financial Performance - As of the latest report, Xinmai Medical's total revenue for the first half of 2025 was 714 million yuan, representing a year-on-year decrease of 9.24% [3]. - The net profit attributable to shareholders for the same period was 315 million yuan, down 22.03% year-on-year, while the non-recurring net profit was 271 million yuan, reflecting a decline of 29.96% [3]. - The company's second-quarter performance showed a revenue of 382 million yuan, a decrease of 10.92% year-on-year, and a net profit of 185 million yuan, down 15.61% [3]. Market Position - Xinmai Medical's total market capitalization is 13.127 billion yuan, which is higher than the industry average of 11.795 billion yuan, ranking 25th in the industry [3]. - The company has a net asset value of 4.058 billion yuan, also above the industry average, ranking 34th [3]. - The price-to-earnings ratio (P/E) stands at 20.86, significantly lower than the industry average of 66.45, ranking 13th [3]. Profitability Metrics - The gross margin for Xinmai Medical is 69.19%, which is substantially higher than the industry average of 51.85%, ranking 22nd [3]. - The net profit margin is 43.48%, far exceeding the industry average of 10.39%, ranking 2nd [3]. - Return on equity (ROE) is reported at 8.16%, compared to the industry average of 1.8%, ranking 12th [3]. Investment Sentiment - In the past 90 days, 11 institutions have rated the stock, with 9 buy ratings and 2 hold ratings, indicating a generally positive outlook despite recent performance [4]. - The average target price set by institutions for Xinmai Medical is 136.03 yuan, suggesting potential upside from the current trading price [4].

Core Viewpoint - The stock of Xinmai Medical (688016) has experienced a decline, with a closing price of 107.63 yuan on October 13, 2025, down 2.67% from the previous day [1] Group 1: Stock Performance and Trading Data - On October 13, 2025, the stock had a turnover rate of 1.46%, with a trading volume of 18,000 hands and a total transaction amount of 193 million yuan [1] - The net inflow of main funds was 7.05 million yuan, accounting for 3.65% of the total transaction amount, while retail investors saw a net outflow of 5.28 million yuan, representing 2.73% of the total [1][2] - Over the past five days, the stock has shown a downward trend, with a closing price of 110.58 yuan on October 10, 2025, down 1.90%, and a net inflow of main funds of 7.95 million yuan [2] Group 2: Financing and Margin Trading Data - On October 13, 2025, the financing balance was 494 million yuan, with a net repayment of 38,300 yuan [3] - The stock had a margin trading balance of 496 million yuan, with a margin balance of 2.39 million yuan [3] - The stock's margin trading data indicates a consistent level of activity, with a total margin trading balance of 496 million yuan over the past five days [3] Group 3: Company Financial Performance - Xinmai Medical reported a main revenue of 714 million yuan for the first half of 2025, a year-on-year decrease of 9.24%, and a net profit of 315 million yuan, down 22.03% [5] - The company's gross profit margin stands at 69.19%, significantly higher than the industry average of 51.85% [5] - The company ranks 15th in net profit within the medical device industry, with a net profit margin of 43.48%, placing it second in the industry [5] Group 4: Industry Comparison and Ratings - Xinmai Medical has a total market value of 13.267 billion yuan, which is above the industry average of 11.888 billion yuan [5] - The company has received 12 ratings from institutions in the past 90 days, with 10 buy ratings and 2 hold ratings, and an average target price of 136.03 yuan [6]

Core Viewpoint - The stock of Xinmai Medical has experienced a decline of 3.81% year-to-date, with a notable drop of 10.95% over the past 20 trading days, indicating potential challenges in the company's performance and market perception [1]. Company Overview - Xinmai Medical, officially known as Shanghai MicroPort CardioFlow MedTech Co., Ltd., was established on August 17, 2012, and went public on July 22, 2019. The company specializes in the research, development, production, and sales of interventional medical devices for aortic and peripheral blood vessels [1]. - The company's revenue composition is primarily from aortic products (71.94%), followed by peripheral and other products (28.04%), with a negligible contribution from other sources (0.02%) [1]. Financial Performance - For the first half of 2025, Xinmai Medical reported a revenue of 714 million yuan, reflecting a year-on-year decrease of 9.24%. The net profit attributable to shareholders was 315 million yuan, down 22.03% compared to the previous year [2]. - Since its A-share listing, Xinmai Medical has distributed a total of 922 million yuan in dividends, with 660 million yuan distributed over the past three years [3]. Shareholder Structure - As of June 30, 2025, the number of shareholders for Xinmai Medical was 17,500, a decrease of 3.61% from the previous period. The average number of tradable shares per shareholder increased by 3.75% to 7,035 shares [2]. - The top ten circulating shareholders include notable entities such as Huabao Zhongzheng Medical ETF and Hong Kong Central Clearing Limited, with increases in holdings compared to the previous period [3].

Group 1 - The core viewpoint of the news is that Xinmai Medical's stock has seen a rise of 5.34%, reaching a price of 112.50 CNY per share, with a total market capitalization of 13.867 billion CNY [1] - Xinmai Medical, established on August 17, 2012, specializes in the research, production, and sales of interventional medical devices for aortic and peripheral blood vessels, with 71.94% of its revenue coming from aortic products and 28.04% from peripheral and other products [1] - The trading volume for Xinmai Medical was 1.33 billion CNY, with a turnover rate of 0.98% [1] Group 2 - According to data, Bosera Fund's ETF, which is among the top ten circulating shareholders of Xinmai Medical, reduced its holdings by 16,300 shares in the second quarter, now holding 524,800 shares, representing 0.43% of the circulating shares [2] - The Bosera Science and Technology Innovation Board 100 ETF Link A (019857) has achieved a year-to-date return of 40.62% and a one-year return of 84.94%, ranking 603 out of 4222 and 516 out of 3795 respectively [2] - The fund manager of Bosera's ETF is Tang Yibing, who has been in the position for 3 years and has overseen a total fund asset size of 9.874 billion CNY [3]

Core Viewpoint - The stock of Xinmai Medical (688016) has experienced a decline of 5.22% as of August 27, 2025, closing at 112.1 yuan, with significant net outflows from major funds and a mixed performance from retail investors [1][2]. Financial Performance - Xinmai Medical reported a main revenue of 714 million yuan for the first half of 2025, a year-on-year decrease of 9.24% - The net profit attributable to shareholders was 315 million yuan, down 22.03% year-on-year - The net profit after deducting non-recurring items was 271 million yuan, a decline of 29.96% year-on-year - In Q2 2025, the company recorded a single-quarter main revenue of 382 million yuan, down 10.92% year-on-year, and a net profit of 185 million yuan, down 15.61% year-on-year [5][6]. Market Activity - On August 27, 2025, the stock had a trading volume of 59,800 lots and a transaction amount of 688 million yuan - Major funds had a net outflow of 63.02 million yuan, accounting for 9.16% of the total transaction amount, while retail investors had a net inflow of 56.06 million yuan, representing 8.15% of the total transaction amount [1][2]. Financing and Margin Trading - On August 27, 2025, the financing balance was 577 million yuan, with a net purchase of 28.30 million yuan - The margin trading balance stood at 579 million yuan, with a short selling volume of 0 shares and a remaining short selling amount of 17,200 shares [3][6]. Industry Comparison - Xinmai Medical's total market value is 13.818 billion yuan, compared to the industry average of 12.081 billion yuan, ranking 25th in the industry - The company has a net asset of 4.058 billion yuan, a net profit of 315 million yuan, and a price-to-earnings ratio of 21.96, significantly lower than the industry average of 73.16, ranking 12th in the industry [4][5].